Disseminated intravascular coagulation is an underestimated but fatal adverse event associated with blinatumomab therapy: A pharmacovigilance analysis of FAERS

Documenti analoghi

• Correction to “Disseminated intravascular coagulation is an underestimated but fatal adverse event associated with blinatumomab therapy: A pharmacovigilance analysis of FAERS ”
  Pubblicazione: (2025)
• Ocular toxicity associated with anti‐HER2 agents in breast cancer: A pharmacovigilance analysis using the FAERS database
  di: Heng Chen, et al.
  Pubblicazione: (2024)
• Reduced‐dose chemotherapy followed by blinatumomab in induction therapy for newly diagnosed B‐cell acute lymphoblastic leukemia
  di: Jing Lu, et al.
  Pubblicazione: (2024)
• Cardiovascular adverse events associated with immune checkpoint inhibitors: A retrospective multicenter cohort study
  di: Yi Zheng, et al.
  Pubblicazione: (2024)
• Regression of kaposiform lymphangiomatosis and chronic disseminated intravascular coagulation after inhaled budesonide‐formoterol treatment
  di: Masaru Imamura, et al.
  Pubblicazione: (2024)